KEYNOTE-177 Final Analysis: First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC

June 4-8, 2021; Online at https://conferences.asco.org/am
In the final analysis from KEYNOTE-177, first-line pembrolizumab was associated with an improved median OS compared with chemotherapy in patients with MSI-H/dMMR mCRC.
Format: Microsoft PowerPoint (.ppt)
File Size: 509 KB
Released: June 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastroesophageal cancers

Manish A. Shah, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

John L. Marshall, MD Released: January 21, 2022

Experts discuss best practices in managing patients with hepatocellular carcinoma (HCC), from Clinical Care Options (CCO)

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: January 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings